期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 77, 期 6, 页码 1038-1046出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2017.07.027
关键词
burden; DLQI; EQ-5D VAS; hidradenitis suppurativa; psoriasis; quality of life; SF-36; TWPI; VAS-pain
类别
资金
- AbbVie Inc.
Background: Psoriasis and hidradenitis suppurativa (HS) exhibit distinct clinical features, but no studies have directly compared the health-related quality of life (HRQoL) in patients with moderate-to-severe manifestations of these conditions. Objective: To determine which disease is associated with more severe HRQoL impairment. Methods: Weighted averages of each of the following baseline HRQoL measures were determined and compared between HS and psoriasis populations from 5 clinical trials: Visual Analog Scale (VAS) for pain, Total Work Productivity Impairment, Dermatology Life Quality Index; EuroQOL 5D VAS, and Short Form-36 Health Survey. Results: Compared with patients with psoriasis, patients with HS reported higher scores for VAS-pain (54.3 vs 36.1 [P < .0001]), Dermatology Life Quality Index (15.3 vs 11.3 [P < .0001]), EuroQOL 5D VAS (58.8 vs 50.8 [P < .0002]), and Total Work Productivity Impairment (35.4 vs 18.2). Patients with HS had lower Short Form-36 Health Survey scores than did patients with psoriasis (physical, 39.6 vs 49.0; mental, 41.5 vs 47.5 [both P < .0001]). Limitations: This analysis was performed using published summary data rather than patient-level data, and weighted pooled averages were compared. Conclusions: Patients with HS have a higher HRQoL burden than patients with psoriasis. This study clearly documents the needs of patients with HS and the potential impact of medical, scientific, and societal consensus for the development of more effective HS treatments.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据